RemedyRepack Recalls Valsartan 320 mg Tablets Due to Carcinogen Impurity
RemedyRepack Inc. is recalling specific lots of Valsartan 320 mg tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a carcinogen impurity, which constitutes a significant health risk and fits the 'Severe' criteria for significant injury/property-damage reports or high-risk contamination.
Plain-English summary
RemedyRepack Inc. is recalling Valsartan 320 mg Tablets (NDC 61786-0793-19) due to Current Good Manufacturing Practice (CGMP) deviations. The recall was initiated because a carcinogen impurity was detected in the active pharmaceutical ingredient (API) used to manufacture the drug product.
The affected product consists of 36 bottles of 90 tablets each (3,240 tablets total) in HDPE 90 cc bottles in cardboard trays. The specific lots subject to recall are B0362988-110917 (exp. 10/2018), B0432265-050318 (exp. 05/2019), B0450321-061218 (exp. 06/2019), B0450322-061218 (exp. 05/2019), and B0408652-030718 (exp. 02/2019).
The product was distributed to three customers in Florida and Virginia. Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the supplier or disposed of according to local regulations. Patients should consult their healthcare provider for alternative treatment options if they have been prescribed this specific medication.
The recalled product
- Product
- Valsartan 320 mg Tablets, HDPE 90 cc bottles in cardboard trays, Rx Only, RemedyRepack, Inc., 625 Kolter Drive, Suite 4, Indiana, PA 15701, NDC 61786-0793-19
- Manufacturer
- RemedyRepack Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot # B0362988-110917
- exp. date 10/2018 Lot # B0432265-050318
- exp. date 05/2019 Lot # B0450321-061218
- exp. date 06/2019 Lot # B0450322-061218
- exp. date 05/2019 Lot # B0408652-030718
- exp. date 02/2019
Distribution
Part of a larger recall action
This product is one of 3 recalled by RemedyRepack Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · RemedyRepack Inc.
See all →- ModerateClindamycin HCl Capsule 300 mg repackaged by RemedyRePack Inc.
FDA (Drugs) · 2025-05-14
- ModerateClindamycin HCl 300 mg Capsule Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-30
- HighCarvedilol 25 mg tablets recalled due to N-nitroso impurity above limit
FDA (Drugs) · 2025-02-12
- HighDuloxetine delayed-release capsules recalled due to manufacturing impurity
FDA (Drugs) · 2025-01-01
- HighPotassium Chloride Extended Release Capsules Recalled for Dissolution Defect
FDA (Drugs) · 2024-07-24
Same hazard · carcinogen impurity
See all →- SevereMacleods Pharma Recalls Losartan Potassium and Hydrochlorothiazide Tablets Due to Carcinogen
FDA (Drugs) · 2019-03-27
- SevereAurobindo Recalls Irbesartan Bulk Ingredient Due to Carcinogen Impurity
FDA (Drugs) · 2018-11-07
- SevereAvKARE Valsartan and Hydrochlorothiazide Tablets Recalled for Carcinogen Impurity
FDA (Drugs) · 2018-09-12
- SevereAvKARE Valsartan and Hydrochlorothiazide Tablets Recalled for Carcinogen Impurity
FDA (Drugs) · 2018-09-12
- SevereAvKARE Valsartan and Hydrochlorothiazide Tablets Recalled for Carcinogen Impurity
FDA (Drugs) · 2018-09-12